Compare Abbott Laboratories (ABT) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs TORM plc — how do they compare? Abbott Laboratories trades at $109.55 (market cap $187.95B), while TORM plc trades at $28.6 (market cap $3.01B). The key difference: Abbott Laboratories is far larger — about 62.4× TORM plc's market cap, and TORM plc pays the higher dividend (9.59%). Which is the better fit depends on your goals.
| ABT | TRMD | |
|---|---|---|
Market Cap | $187.95B | $3.01B |
Sector | Health | Technology |
52-Week High | $136.62 | $34.87 |
52-Week Low | $82.57 | $18.77 |
Enterprise Value | $214.96B | $3.89B |
Dividend Yield | 2.32% | 9.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
TRMD trades at $29.49 with a neutral daily change. The stock shows strong fundamentals with a P/E of 8.57, net income margin of 24.41%, and ROE of 15.62%, though recent Q1 2026 EPS missed expectations. Technical indicators are bearish overall, with support at $28 and resistance at $30. Recent news highlights strong Q1 2026 results and a dividend of $0.70 per share.
The outlook is positive with 100% analyst buy ratings and robust cash flow, but risks include earnings volatility and market sentiment. The stock offers value through dividends and growth potential, yet investors should monitor earnings consistency and macroeconomic factors affecting the tanker market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
